Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Bill H Chang
Affiliation
Oregon Health and Science University
ORCID
Career Start Year
1993
Papers
58
H Index
29
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36912490
Disseminated fungal disease caused by Magnusiomyces clavatus in a pediatric cancer patient: Case report and review of the literature.
Pediatr Blood Cancer
2023
37698624
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Blood Cancer Discov
2023
37199721
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.
Clin Cancer Res
2023
36813993
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
Leukemia
2023
35078224
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.
Blood Adv
2022
35868306
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Cancer Cell
2022
35180323
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Am J Hematol
2022
32898857
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Blood
2021
34233449
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia.
Haematologica
2021
33438318
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Pediatr Blood Cancer
2021
33220230
In Regard to Wong et al.
Int J Radiat Oncol Biol Phys
2020
31969338
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Clin Cancer Res
2020
32094466
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Leukemia
2020
31048320
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Cancer Discov
2019
31698451
Replication timing alterations in leukemia affect clinically relevant chromosome domains.
Blood Adv
2019
31267709
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche.
EMBO Rep
2019
30810217
Phenotype switch in acute lymphoblastic leukaemia associated with 3Â years of persistent CAR T cell directed-CD19 selective pressure.
Br J Haematol
2019
29728694
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Leukemia
2018
29812996
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
J Clin Oncol
2018
30018082
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Sci Signal
2018
29849118
Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
Oncogene
2018
30333627
Functional genomic landscape of acute myeloid leukaemia.
Nature
2018
28669224
Development and field testing of a smartphone "App" for tinnitus management.
Int J Audiol
2017
28433605
Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
Exp Hematol
2017
28122742
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Blood
2017
29190164
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.
Pediatr Hematol Oncol
2017
28805662
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
J Clin Invest
2017
26920889
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Clin Cancer Res
2016
27705940
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Oncotarget
2016
27582059
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sci Transl Med
2016
25728418
Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML).
Pediatr Blood Cancer
2015
26067326
Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.
Sci Rep
2015
26032424
Therapeutically Targetable ALK Mutations in Leukemia.
Cancer Res
2015
26108689
Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.
Leukemia
2015
25895498
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.
J Hematol Oncol
2015
25662999
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Pediatr Blood Cancer
2015
25759025
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
Cancer Cell
2015
23087056
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.
Cancer Res
2013
24286512
Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine.
Genome Med
2013
23656643
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
N Engl J Med
2013
23471820
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Cancer Discov
2013
21960246
Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
Leukemia
2012
23153538
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
Cancer Cell
2012
22628462
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia.
Genome Res
2012
22299775
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Br J Haematol
2012
22038978
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Pediatr Blood Cancer
2012
19433805
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proc Natl Acad Sci U S A
2009
17612542
Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant.
Int J Gynaecol Obstet
2008
18237230
A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type.
Pediatr Dev Pathol
2008
17001311
Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability.
Oncogene
2007
1 - 50 of 58
Column Actions
Search
Recommended Authors
Chelsea Mayoh
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year
2016
Number of shared co-authors
3
Thai Hoa Tran
Universite de Montreal
Career Start Year
2013
Number of shared co-authors
11
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year
2010
Number of shared co-authors
7
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year
2009
Number of shared co-authors
1
Amanda Winters
University of Colorado School of Medicine
Career Start Year
2008
Number of shared co-authors
7
Kara L Davis
Stanford University School of Medicine
Career Start Year
2008
Number of shared co-authors
5
Emmanuelle Clappier
Saint-Louis Hospital
Career Start Year
2005
Number of shared co-authors
0
Yana Pikman
Dana Farber Cancer Institute
Career Start Year
2005
Number of shared co-authors
7
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year
2005
Number of shared co-authors
28
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year
2004
Number of shared co-authors
15
Giovanni Roti
University of Parma
Career Start Year
2003
Number of shared co-authors
3
Christopher C Porter
Emory University School of Medicine
Career Start Year
2003
Number of shared co-authors
7
Thomas Ernst
Universitatsklinikum Jena
Career Start Year
2002
Number of shared co-authors
3
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year
2000
Number of shared co-authors
8
David M Weinstock
Merck & Co.
Career Start Year
1998
Number of shared co-authors
13
Scott C Borinstein
Vanderbilt University Medical Center
Career Start Year
1998
Number of shared co-authors
1
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year
1997
Number of shared co-authors
0
Kathryn Evans
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year
1996
Number of shared co-authors
4
Yongjin Li
Mayo Clinic
Career Start Year
1995
Number of shared co-authors
11
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year
1995
Number of shared co-authors
15
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year
1993
Number of shared co-authors
1
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year
1992
Number of shared co-authors
3
John Easton
St Jude Children's Research Hospital
Career Start Year
1991
Number of shared co-authors
12
Ricky W Johnstone
The University of Melbourne
Career Start Year
1990
Number of shared co-authors
4
Glenn M Marshall
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year
1989
Number of shared co-authors
3
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year
1989
Number of shared co-authors
33
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year
1987
Number of shared co-authors
8
David M Loeb
Children's Hospital at Montefiore.
Career Start Year
1986
Number of shared co-authors
5
Ching-Hon Pui
St. Jude Children's Research Hospital
Career Start Year
1980
Number of shared co-authors
12
Gregory H Reaman
National Cancer Institute
Career Start Year
1978
Number of shared co-authors
10
row(s) 1 - 30 of 30
Collaborators
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers
26
Brian J Druker
Oregon Health & Science University
Co-authored papers
25
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
14
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
11
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers
10
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
8
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
7
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
7
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
6
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers
6
Nicola Long
Oregon Health and Science University
Co-authored papers
5
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers
5
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
5
Jessica Leonard
Oregon Health & Science University
Co-authored papers
5
Mignon L Loh
University of Washington
Co-authored papers
4
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
4
Jade Bryant
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
4
Kara Johnson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
4
Alexey V Danilov
City of Hope National Medical Center
Co-authored papers
4
David S Ziegler
Co-authored papers
4
Jason Glover
Randall Children's Hospital
Co-authored papers
4
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
4
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers
4
Peter Kurre
Children's Hospital of Philadelphia
Co-authored papers
4
Stephen P Hunger
Children's Hospital of Philadelphia
Co-authored papers
4
Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
4
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers
4
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Co-authored papers
4
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers
3
Joelle Wolf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers
3
1 - 30